What is LXRX's current stock price?

LXRX (Lexicon Pharmaceuticals, Inc.) is currently trading at $2.16 with a market cap of $959.5M.

What sector is Lexicon Pharmaceuticals, Inc. in?

Lexicon Pharmaceuticals, Inc. (LXRX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is LXRX a good stock to buy?

Analysts have a Hold consensus on LXRX with a price target of $6.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

LXRX Lexicon Pharmaceuticals, Inc.

Healthcare

$2.16-3.14%ClosedMarket Cap: $959.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.26

P/S

13.78

EV/EBITDA

-48.05

DCF Value

$-10.36

FCF Yield

-4.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

99.1%

Operating Margin

-34.8%

Net Margin

-37.5%

ROE

-18.6%

ROA

-9.7%

ROIC

-9.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$21.1M	$-1.0M	$—
Q4 null	$5.5M	$-15.5M	$—
FY null	$49.8M	$-50.3M	$—
Q3 null	$14.2M	$-12.8M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$6.00 - $6.00

1 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell

CitigroupBuy

2026-05-11

HC Wainwright & Co.Buy

2026-03-23

CitigroupBuy

2026-03-10

HC Wainwright & Co.Buy

2025-09-02

CitigroupBuy

2025-08-07

Trading Activity

Insider Trades

View All

Artal Participations S.a r.l.director, 10 percent owner:

SellFri May 08

Artal Participations S.a r.l.director, 10 percent owner:

SellFri May 08

Artal Participations S.a r.l.director, 10 percent owner:

SellFri May 08

Swain Judith Ldirector

SellMon May 04

Swain Judith Ldirector

SellMon May 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.97

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Peers